Of the remaining 167 tumours, 30 were classified as MMRd–POLEmut ECs and will be reported separately (León‐Castillo et al18), leaving 138 tumours (3.9%) that were assigned a provisional status of multiple‐classifier with abnormal p53 (mutant p53 expression by IHC or a mutation in TP53). This evidence concerns the gene TP53 and neoplasm.